In methionine/choline-deficient diet-fed mice, two-week treatment with a dual GLP-1/glucagon co-agonist (G49) ameliorated NASH by reducing inflammation, steatosis, oxidative stress, and apoptosis and increased mitochondrial biogenesis [205]. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.